Table of Contents
Executive Summary — 5
SWOT
Analysis — 6
Algeria Pharmaceuticals And Healthcare
Industry SWOT — 6
Pharmaceutical Business Environment
Ratings — 7
Table: Middle East And Africa (MEA) –
Regional Pharmaceutical Business Environment Ratings for
Q409 — 7
Limits Of Potential
Returns — 8
Risks To Realisation Of
Returns — 8
Algeria – Market
Summary — 10
Regulatory Regime — 12
Trade Agreements — 13
Intellectual Property
Environment — 13
Intellectual Property
Shortcomings — 14
Pricing And Reimbursement
Regime — 16
Industry Trends And
Developments — 17
Epidemiology — 17
Table Algeria – Top 10 Causes Of Death For All Ages
(2002) — 17
Healthcare Sector — 18
Healthcare Sector Reforms — 19
Pharmaceutical
Wholesale — 20
Pharmaceutical
Retail — 20
Biotechnology And
Research — 21
Medical Devices — 21
Industry Forecast Scenario — 22
Overall Market
Forecast — 22
Table: Algeria – Drug Expenditure
Indicators, Historical Data and Forecasts — 23
Key Growth
Factors – Industry — 24
Table: Algeria - Health
Expenditure Indicators, Historical Data and Forecasts — 25
Key Growth Factors – Macroeconomic Forecast — 26
Table: Algeria - Economic Activity — 28
Prescription
Market Forecast — 29
Table: Algeria – Prescription
Market Indicators, Historical Data and Forecasts (DZDmn unless otherwise
stated) — 30
Patented Drug Market
Forecast — 31
Table: Algeria - Patented Drug Market
Indicators, Historical Data and Forecasts — 31
Generics
Market Forecasts — 32
Table: Algeria – Generics
Market Indicators, Historical Data and Forecasts — 32
OTC
Market Forecast — 33
Table: Algeria - OTC Market
Indicators, Historical Data and Forecasts (DZDmn unless otherwise
stated) — 34
Pharmaceutical Trade
Forecasts — 35
Table: Algeria - Pharmaceutical Trade
Indicators, Historical Data and Forecasts (US$mn) — 36
Other Healthcare Data Forecasts — 37
Table: Algeria
– Other Healthcare Indicators, Historical Data And
Forecasts — 37
Key Risks To BMI’s Forecast
Scenario — 38
Key Risks To BMI’s Forecast
Scenario — 38
Competitive
Landscape — 39
Table Leading Pharmaceutical Companies In
Algeria — 40
Domestic Pharmaceutical
Sector — 40
Recent Domestic Pharmaceutical Sector
Developments — 41
Foreign Pharmaceutical
Sector — 43
Recent Foreign Pharmaceutical Sector
Developments — 44
Company
Profiles — 46
Leading
Multinationals — 46
Sanofi-Aventis — 46
GlaxoSmithKline
(GSK) — 48
Pfizer — 49
Novartis — 51
Merck & Co — 52
Leading
Indigenous Manufacturer — 53
Groupe
Saidal — 53
Country Snapshot: Algeria Demographic
Data — 55
Section 1: Population — 55
Table: Demographic Indicators, 2005-2030 — 55
Table:
Rural/Urban Breakdown, 2005-2030 — 56
Section 2: Education
And Healthcare — 56
Table: Education Levels,
2002-2025 — 56
Table: Healthcare – Vital Statistics,
2005-2030 — 56
Section 3: Labour Market And Spending
Power — 57
Table: Employment Indicators,
2001-2006 — 57
Table: Consumer Expenditure, 2000-2012
(US$) — 58
BMI Methodology — 59
How We
Generate Our Pharmaceutical Industry Forecasts — 59
Pharmaceutical Business Environment Ratings
Methodology — 60
Ratings Overview — 60
Table: Pharmaceutical Business Environment Indicators — 61
Weighting — 62
Table: Weighting Of
Components — 62
Sources — 62
| 
View Cart
